Optimi Health Completes Third Commercial Psilocybin Export to Australia
OPTH sits 42% above its 52-week low of $3 on elevated volume (3.0× avg).
Summary
Optimi Health has completed its third commercial export of 1,000 5mg psilocybin capsules to Australia for patients with treatment-resistant depression. This follows Australia's Therapeutic Goods Administration (TGA) expanding access to psychedelics in May and Optimi's earlier GMP production of these capsules in June. The recurring shipments demonstrate ongoing commercialization and revenue generation in a key regulated market, solidifying Optimi's position as a supplier in the nascent psychedelic medicine space.
At the time of this announcement, OPTH was trading at $4.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23M. The 52-week trading range was $3.00 to $8.84. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.